Nepal, Sept. 18 -- During Thursday's trading session, shares of one of the leading globally vertically integrated pharmaceutical companies with a focus on R&D to manufacture niche and complex molecules surged nearly 5 percent on BSE, after the U.S. Food and Drug Administration (FDA) closed inspection without urging action.

At 11:46 a.m., the shares of NATCO Pharma Limited were trading in the green at Rs. 885.05 on BSE, up by around 3 percent, as against its previous closing price of Rs. 857.5, with a market cap of Rs. 15,852 crores. The stock has delivered negative returns of around 42 percent in one year, but has gained by over 1 percent in the last one month.

What's the News As per the latest regulatory filings, NATCO Pharma Limited a...